NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03434379,A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT03434379,IMbrave150,COMPLETED,This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have received no prior systemic treatment.,YES,"Carcinoma, Hepatocellular",DRUG: Atezolizumab|DRUG: Bevacizumab|DRUG: Sorafenib,"Overall Survival (OS) in the Global Population, OS was defined as the time from randomization to death from any cause., From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months)|Progression Free Survival by Independent Review Facility-Assessment (PFS-IRF) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in the Global Population, PFS was defined as the time from randomization to the first occurrence of progressive disease (PD) or death from any cause whichever occurs first as determined by an IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm)., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|Overall Survival (OS) in the China Population, OS was defined as the time from randomization to death from any cause., From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months)|PFS-IRF Per RECIST v1.1 in the China Population, PFS was defined as the time from randomization to the first occurrence of progressive disease (PD) or death from any cause whichever occurs first as determined by an IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm)., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)","Objective Response Rate by IRF-Assessment (ORR-IRF) Per RECIST v1.1 in the Global Population, ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR, Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)|Objective Response Rate by IRF-Assessment (ORR-IRF) Per Hepatocellular Carcinoma (HCC) Modified RECIST (mRECIST) in the Global Population, ORR was defined as the percentage of participants with CR or PR as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver measuring only the residual vital tumor mass in the liver. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR, Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)|ORR by Investigator-Assessment (ORR-INV) Per RECIST v1.1 in the Global Population, ORR was defined as the percentage of participants with CR or PR as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR, Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)|Duration of Response by IRF-Assessment (DOR-IRF) Per RECIST v1.1 in the Global Population, DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 mm., Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)|Duration of Response by IRF Assessment (DOR-IRF) Per HCC mRECIST in the Global Population, DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 mm., Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)|Duration of Response by Investigator Assessment (DOR-INV) Per RECIST v1.1 in the Global Population, DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 mm., Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)|PFS-IRF Per HCC mRECIST in the Global Population, PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm)., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|PFS by Investigator Assessment (PFS-INV) Per RECIST v1.1 in the Global Population, PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm)., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|Time to Progression (TTP) by IRF Assessment (TTP-IRF) Per RECIST v1.1 in the Global Population, Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm)., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|TTP-IRF Per HCC mRECIST in the Global Population, Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm)., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|TTP by Investigator Assessment (TTP-INV) Per RECIST v1.1 in the Global Population, Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm)., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|Overall Survival by Baseline AFP in the Global Population, OS was defined as the time from randomization to death from any cause. Subpopulations with baseline AFP \<400 ng/mL and AFP\>/= 400 ng/mL were analyzed., From randomization to death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|PFS-IRF Per RECIST v1.1 by Baseline AFP in the Global Population, PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm). Subpopulations with baseline AFP \<400 ng/mL and AFP\>/= 400 ng/mL were analyzed., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|PFS-INV Per RECIST v1.1 by Baseline AFP in the Global Population, PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm). Subpopulations with baseline AFP \<400 ng/mL and AFP\>/= 400 ng/mL were analyzed., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|Time to Deterioration (TTD) in the Global Population, TTD was defined as the time from randomization to the first deterioration (decrease from baseline of \>/= 10 points) in the patient-reported health-related global health status/quality of life (GHS /HRQoL), physical function or role function scales of the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for cancer (EORTC) QLQ-C30, maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|Number of Participants With Adverse Events (AEs) in the Global Population, An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events., Up to end of study (up to approximately 56 months)|Maximum Serum Concentration (Cmax) of Atezolizumab at Cycle 1 in the Global Population, Post-dose on Day 1 of Cycle 1 (cycle length = 21 days)|Trough Serum Concentration (Cmin) of Atezolizumab in the Global Population, Pre-dose on Day 1 of Cycles 2, 3, 4, 8, 12 and 16 (cycle length = 21 days)|Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the Global Population, Baseline and post-baseline on Day 1 (pre-dose) of Cycles 2, 3, 4, 8, 12, 16 (cycle length = 21 days) and treatment discontinuation visit (up to approximately 30 months)|Objective Response Rate by IRF-Assessment (ORR-IRF) Per RECIST v1.1 in the China Population, ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR, Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)|Objective Response Rate by IRF-Assessment (ORR-IRF) Per Hepatocellular Carcinoma (HCC) Modified RECIST (mRECIST) in the China Population, ORR was defined as the percentage of participants with CR or PR as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver measuring only the residual vital tumor mass in the liver. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR, Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)|ORR by Investigator-Assessment (ORR-INV) Per RECIST v1.1 in the China Population, ORR was defined as the percentage of participants with CR or PR as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR, Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)|Duration of Response by IRF-Assessment (DOR-IRF) Per RECIST v1.1 in the China Population, DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 mm., Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)|Duration of Response by IRF Assessment (DOR-IRF) Per HCC mRECIST in the China Population, DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 mm., Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)|Duration of Response by Investigator Assessment (DOR-INV) Per RECIST v1.1 in the China Population, DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 mm., Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)|PFS-IRF Per HCC mRECIST in the China Population, PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm)., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|PFS by Investigator Assessment (PFS-INV) Per RECIST v1.1 in the China Population, PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm)., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|Time to Progression (TTP) by IRF Assessment (TTP-IRF) Per RECIST v1.1 in the China Population, Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm)., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|TTP-IRF Per HCC mRECIST in the China Population, Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm)., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|TTP by Investigator Assessment (TTP-INV) Per RECIST v1.1 in the China Population, Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm)., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|Time to Deterioration (TTD) in the China Population, TTD was defined as the time from randomization to the first deterioration (decrease from baseline of \>/= 10 points) in the patient-reported health-related global health status/quality of life (GHS /HRQoL), physical function or role function scales of the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for cancer (EORTC) QLQ-C30, maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks., Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)|Number of Participants With Adverse Events (AEs) in the China Population, An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events., Up to end of study (up to approximately 56 months)|Maximum Serum Concentration (Cmax) of Atezolizumab in the China Population, Post-dose on Day 1 of Cycle 1 (cycle length = 21 days)|Trough Serum Concentration (Cmin) of Atezolizumab in the China Population, Pre-dose on Day 1 of Cycles 2, 3, 4, 8, 12 and 16 (cycle length = 21 days)|Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the China Population, Baseline and post-baseline on Day 1 (pre-dose) of Cycles 2, 3, 4, 8, 12, 16 (cycle length = 21 days) and treatment discontinuation visit (up to approximately 18 months)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,558,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,YO40245|2017-003691-31,2018-03-15,2020-08-31,2022-11-17,2018-02-15,2021-11-05,2023-10-23,"St. Josephs Hospital and Medical Center, Phoenix, Arizona, 85260, United States|City of Hope, Duarte, California, 91010, United States|Uni of California - San Diego; Cancer Center & Dept of Medicine, La Jolla, California, 92093, United States|Kaiser Permanente Northern California, Novato, California, 94589, United States|University of California Irvine Medical Center, Orange, California, 92868, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, 95825, United States|California Pacific Medical Center, San Francisco, California, 94115, United States|Kaiser Permanente - San Francisco Medical Center, San Francisco, California, 94118, United States|University of California Los Angeles, Santa Monica, California, 90404, United States|Kaiser Permanente - Walnut Creek, Walnut Creek, California, 94596, United States|Banner MD Anderson Cancer Center, Greeley, Colorado, 85234, United States|Georgetown University, Washington, District of Columbia, 20007, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, 63110, United States|University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, 87102, United States|Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York, New York, 10016, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|M.D Anderson Cancer Center; Uni of Texas At Houston, Houston, Texas, 77030, United States|Swedish Cancer Inst., Seattle, Washington, 98104, United States|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, 2200, Australia|St George Hospital, Kogarah, New South Wales, 2217, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, 5011, Australia|Sunshine Hospital, St Albans, Victoria, 3021, Australia|Ottawa Hospital Research Institute, Ottawa, Ontario, K1Y 4E9, Canada|Centre hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, H2X 0A9, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|McGill University Health Centre - Glen Site, Montreal, Quebec, H4A 3J1, Canada|Peking Union Medical College Hospital, Beijing City, 100032, China|Beijing Friendship Hospital, Beijing, 100050, China|Beijing Cancer Hospital, Beijing, 100142, China|the First Hospital of Jilin University, Changchun, 130021, China|Jilin Cancer Hospital, Changchun, 132013, China|Hunan Cancer Hospital, Changsha CITY, 410013, China|The First People's Hospital of Foshan; Local Ethic Committee, Foshan, 510000, China|The 900th Hospital of PLA joint service support force, Fuzhou, 110016, China|Sun Yet-sen University Cancer Center, Guangzhou City, 510663, China|Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China|Sir Run Run Shaw Hospital, Hangzhou City, 310018, China|Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department, Hangzhou City, 310022, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, 310003, China|Harbin Medical University Cancer Hospital, Harbin, 150081, China|Anhui Province Cancer Hospital, Hefei City, 230031, China|The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China|General Hospital of Jinan Military Command of PLA, Jinan, 250031, China|The 81st Hospital of P.L.A., Nanjing City, 210002, China|Fudan University Shanghai Cancer Center, Shanghai City, 200120, China|Zhongshan Hospital Fudan University, Shanghai, 200032, China|Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech, Wuhan, 430030, China|Masarykuv onkologicky ustav, Brno, 656 53, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, 779 00, Czechia|Hopital Claude Huriez;Gastro Enterologie, Lille, 59037, France|Hopital De La Croix Rousse; Hepatologie Gastro Enterologie, Lyon, 69317, France|Hopital Timone Adultes; Gastro Enterologie, Marseille, 13385, France|Hopital Saint-Eloi; Hepatologie-Gastro-Enterologie, Montpellier, 34295, France|Hopital Hotel Dieu Et Hme; Hepatologie Gastro Enterologie, Nantes, 44093, France|CHU Nice - Hôpital de l'Archet 2; service Hepato gastro enterologie, Nice Cedex, 06202, France|Hopital Charles Nicolle; Gastroenterologie, Rouen, 76031, France|Hopital Hautepierre; Gastro Enterologie, Strasbourg, 67098, France|Hôpital d'Adultes; Service hépato-gastro-entérologie, Vandoeuvre-les-nancy, 54511, France|Institut Gustave Roussy; Gastro-Enterologie, Villejuif, 94805, France|Campus Virchow-Klinikum Charité Centrum 13; Medizinische Klinik; Abt.Hepatologie u.Gastroenterologie, Berlin, 13353, Germany|Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik I, Frankfurt, 60590, Germany|Universitaetsklinikum Hamburg-Eppendorf; I. Medizinische Klinik - Gastroenterologie, Hamburg, 20246, Germany|Med. Hochschule Hannover; Gastroenterologie, Hannover, 30625, Germany|Universitätsklinikum Leipzig Medizinische Klinik II Gastroenterolog. u. Hepatolog., Leipzig, 04103, Germany|Uniklinik Mainz; I. Medizinische Klinik, Mainz, 55131, Germany|Klinikum der Uni Regensburg; Klinik f.Innere Medizin I Abt. Hämatologie und Internistische Onkologie, Regensburg, 93053, Germany|Queen Mary Hospital; Dept. Of Haematology & Oncology, Hong Kong, Hong Kong|Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong|Az. Osp. Rummo; Oncologia Medica, Benevento, Campania, 82100, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, 47014, Italy|Az. Osp. S. Luigi Gonzaga; Divisione Di Oncologia Medica, Orbassano, Piemonte, 10043, Italy|A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia, Cagliari, Sardegna, 09100, Italy|Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria ? Polo Oncologico, Pisa, Toscana, 56126, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima, Padova, Veneto, 35128, Italy|Chiba University Hospital, Chiba, 260-8677, Japan|National Cancer Center Hospital East, Chiba, 277-8577, Japan|Kurume University Hospital, Fukuoka, 830-0011, Japan|Sapporo Kosei Genaral Hospital, Hokkaido, 060-0033, Japan|Hokkaido University Hospital, Hokkaido, 060-8648, Japan|Kanazawa University Hospital, Ishikawa, 920-8641, Japan|Kitasato University Hospital, Kanagawa, 252-0375, Japan|Kumamoto University Hospital, Kumamoto, 860-8556, Japan|Osaka Metropolitan University Hospital, Osaka, 545-8586, Japan|Kindai University Hospital, Osaka, 589-8511, Japan|Saga-ken Medical Centre Koseikan, Saga, 840-8571, Japan|Shizuoka Cancer Center, Shizuoka, 411-8777, Japan|Japanese Red Cross Musashino Hospital, Tokyo, 180-8610, Japan|Chonnam National University Hwasun Hospital, Jeollanam-do, 58128, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Ulsan University Hosiptal, Ulsan, 44033, Korea, Republic of|Copernicus Podmiot Medyczny Sp. z o.o. Wojewodzkie Centrum Onkologii, Gdansk, 80-219, Poland|ID Clinic, Myslowice, 41-400, Poland|SP ZOZ MSWiA z WARMINSKO-MAZURSKIM CENTRUM ONKOLOGII; CLINICAL ONCOLOGY, CLINICAL IMMUNOLOGY, Olsztyn, 10-228, Poland|Narodowy Instytut Onkologii im. Marii Sk?odowskiej-Curie - Pa?stwowy Instytut Badawczy, Warszawa, 02-781, Poland|Dolno?l?skie Centrum Onkologii; Oddzia? Onkologii Klinicznej i Chemioterapii, Wroc?aw, 53-413, Poland|FSBI ""National Medical Research Center of Oncology N.N. Blokhin?; Clinical Biotechnologies, Moscow, Moskovskaja Oblast, 115478, Russian Federation|GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology), Saint Petersburg, Sankt Petersburg, 197758, Russian Federation|National Cancer Centre, Singapore, 169610, Singapore|Tan Tock Seng Hospital; Oncology, Singapore, 308433, Singapore|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, 08035, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, 28040, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, 28046, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, 28050, Spain|Hospital Universitario Miguel Servet; Servicio de Oncologia Medica, Zaragoza, 50009, Spain|National Cheng Kung University Hospital; Oncology, Tainan, 00704, Taiwan|Chi-Mei Medical Centre; Hematology & Oncology, Tainan, 710, Taiwan|Veterans General Hospital; Cancer Center, Taipei, 00112, Taiwan|National Taiwan Uni Hospital; Dept of Oncology, Taipei, 100, Taiwan|Chang Gung Memorial Hospital-Linkou; Dept of Oncology, Taoyuan County, 333, Taiwan|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Royal Free Hospital; Dept of Oncology, London, NW3 2QG, United Kingdom|King'S College Hospital, London, SE5 9RS, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, M2O 4BX, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/79/NCT03434379/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/79/NCT03434379/SAP_001.pdf"
